TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged 18 years or above~* Patients scheduled for elective total hip replacement~Exclusion Criteria:~* Planned, staged total bilateral hip replacement~* Active bleeding or high risk of bleeding contraindicating treatment with low molecular weight heparin~* Contraindication listed in the labeling or conditions precluding patient treatment with enoxaparin~* Conditions prohibiting bilateral venography (e.g. amputation of one leg, allergy to contrast media)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SUPPORT FOR FRAIL ELDERLY PERSONS - From Prevention to Palliation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 80 years of age or older living in the community.~* The participants should live in their ordinary housing~* Independent on formal support~* Independent on informal support~* Cognitive intact defined as a Mini Mental Test score \> 25

- Gender: ALL
- Minimum Age: 80 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1.Preventive home visit (Type: EXPERIMENTAL): Preventive home visits: This intervention included a single home visit made by either a nurse, a physiotherapist, a qualified social worker or an occupational therapist. Participants received verbal and written information/advice about what the districts could provide. The preventive home visit was guided by a protocol, which included an opportunity for individuals to further elaborate on certain elements. The visit lasted between one and a half to two hours.
- 2. Senior meetings (Type: EXPERIMENTAL): The senior meetings comprised four weekly meetings with about six participants in each group. The main purpose was to focus on two different topics: 1) information about the ageing process and its consequences and 2) provision of tools and strategies for solving problems that can arise in the home environment. A follow-up home visit took place two to three weeks after the group sessions were completed. The group meetings were led either by an occupational therapist, a registered nurse, a physiotherapist or a qualified social worker, all of whom spoke about their particular dimension of aging.
- 3. Control group (Type: NO_INTERVENTION): The control group had access to the ordinary range of services if requested from the urban districts for the aged. The aim of the municipal provision of care for the older persons is to ensure the ability to live as independently as possible. This includes remaining in their homes. When an older person in Sweden has difficulties managing independently, she or he can apply for assistance from the district. The extent of such support is subject to an assessment of needs and includes meals on wheels, help with cleaning and shopping, assistance with personal care, safety alarms and transportation service. The older person are also offered healthcare, provided either by municipal home help or home medical care services.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adaptation of Ca-HELP Intervention in Rural Geriatric Cancer Patient Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Patient Inclusion Criteria:~* 65 years of age or older~* Diagnosed with cancer~* English speaking~* Reside in non-institutional, rural settings~* Receive care at community-based clinic in rural area~* Ability to provide informed consent~* Have identified an informal caregiver.~Patient Exclusion Criteria:~* Severe cognitively impairment (Short Portable Mental Status Questionnaire scores of \<6);~* Receiving hospice at time of enrollment.~Caregiver eligibility criteria include the following~* The person (family member or friend) whom the patient indicates provides most of their informal care~* Able to provide informed consent.~Provider eligibility criteria:~-Currently works with geriatric cancer patients OR in a healthcare system serving this patient population. Providers will include social workers, nurses, oncologists, and healthcare administrators.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ca-HELP (Type: EXPERIMENTAL): This intervention arm will consist of six components: (1) Assessment of current knowledge, attitudes, and preferences; (2) clarification and correction of misconceptions about cancer pain control; (3) teaching of relevant concepts (education about cancer pain control); (4) planning (identifying goals of care, creating achievable goals of care, and creating strategies to communicate goals of care to providers and family members); (5) rehearsal of communication strategies using role play exercises; and (6) portrayal of learned skills (patient applies skills in visit with healthcare provider).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* At least 18 years old (inclusive)~* Weigh \>55 kg and have a body mass index (BMI) ≤38.0 kg/m2~* Diagnosed with PNH (white blood cell (WBC) clone \>10%)~* Lactose dehydrogenase (LD) ≥2 times the upper limit of normal~* Last transfusion within 12 months prior to screening~* Platelet count of \>30,000/mm3~* Absolute neutrophil count \>cells/500 µL~* Women of child-bearing potential (WOCBP) must have a negative pregnancy test at screening and must agree to use protocol defined methods of contraception for the duration of the study~* Males must agree to use protocol defined methods of contraception and agree to refrain from donating sperm for the duration of the study~* Able to provide documentary evidence of Neisseria meningitidis, Pneumococcal conjugate vaccine (multivalent) or Pneumococcal polysaccharide vaccine 23 (PCV13 or PPSV23) and Haemophilus influenzae Type B (Hib) vaccination within 2 years prior to Day 1 dosing, OR willing to receive vaccinations against Neisseria meningitidis at least two weeks prior to dosing on Day 1 with a booster on Day 57, and PCV13 and Hib vaccines at least two weeks prior to dosing on Day 1.~* Willing and able to give informed consent~Exclusion Criteria:~* Prior eculizumab (Soliris)® treatment~* Active bacterial infection~* Known infection with hepatitis B, hepatitis C or human immunodeficiency virus (HIV)~* Hereditary complement deficiency~* History of bone marrow transplantation~* Concurrent severe aplastic anemia (SAA), defined as currently receiving immunosuppressive therapy for SAA including but not limited to cyclosporin A, tacrolimus, mycophenolate mofetil or anti-thymocyte globulin.~* Participation in any other investigational drug trial or exposure to another investigational agent, device or procedure within 30 days~* Evidence of QTcF prolongation defined as \>450 ms for males and \>470 ms for females at screening~* Creatinine clearance (CrCl) \<50 mL/min (Cockcroft-Gault formula) at screening~* Breast-feeding women~* History of meningococcal disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): 180 mg pegcetacoplan/day
- Cohort 2 (Type: EXPERIMENTAL): 270 mg pegcetacoplan/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Adult participants with type 2 diabetes mellitus (T2DM) inadequately controlled with OADs therapy with/without GLP-1 receptor agonist at stable dose for at least 3 months.~* Signed written informed consent.~Exclusion criteria:~* Age \<18 years.~* HbA1c \<7.5% or \>10.5% (at screening visit). Body mass index (BMI) \<25 kg/m\^2 or \>40 kg/m\^2.~* History of T2DM for less than 1 year before screening.~* Less than 6 months before screening on OADs treatment and GLP-1 receptor agonist (if taken).~* Current or previous insulin use except for a maximum of 8 consecutive days or totally 15 days (eg, acute illness, surgery) during the last year prior to screening.~* Initiation of new glucose-lowering medications and/or weight loss drug in the last 3 months before screening visit.~* Participant receiving only noninsulin antihyperglycemic drugs not approved for combination with insulin according to local labelling/local treatment guideline.~* History of hypoglycemia unawareness or repeated episodes of severe hypoglycemia or metabolic acidosis, including hospitalization for diabetic ketoacidosis during the last 12 months prior to screening.~* Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eg, laser, surgical treatment, or injectable drugs) during the study period.~* End stage renal disease.~* Any acute or chronic condition that in the opinion of Investigator would affect the safety of participant, compliance, or study results.~* Any contraindication to use of Toujeo® or Tresiba® as defined in the national product label, hypersensitivity to Toujeo® or Tresiba® active ingredients or one of the excipients.~* Pregnant or breast-feeding women.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Toujeo (Type: EXPERIMENTAL): Toujeo® (Insulin glargine, 300 U/mL) subcutaneous (SC) injection once daily up to Week 24 on top of non-insulin antidiabetic treatment.
- Tresiba (Type: ACTIVE_COMPARATOR): Tresiba® (Insulin Degludec, 100 U/mL) SC injection once daily up to Week 24 on top of non-insulin antidiabetic treatment .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy for Patients With Cancer of the Stomach

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~1. Histological proven adenocarcinoma of the esophagus or the ventricle (ECV), and which cannot be treated curatively.~2. Age ≥ 18 years.~3. WHO performance status 0-1.~4. Neutrophils ≥ 1,5 x 109/L and platelets ≥ 100 x 109/L.~5. Bilirubin ≤ 1,5 x UNL (Upper Normal Limit) and ASAT and/or ALAT ≤ 3 x UNL.~6. Creatinine-clearance ≥ 60 ml/min.~7. Planned first day of treatment within 8 days after inclusion in the study.~8. Signed consent form.~Exclusion Criteria:~1. No previous treatment with chemotherapy, except for (neo)-adjuvant chemotherapy for adenocarcinoma - treatment should have been completed at least 6 months before entrance in this study.~2. No sensory neuropathy.~3. No previously treatment with docetaxel, oxaliplatin or S1.~4. No clinical suspicion of brain metastases.~5. No cytotoxic treatment or other experimental treatment within 2 weeks of inclusion in the study.~6. Other serious disease (i.e. heart disease, AMI within 1 year or ongoing infection).~7. No pregnant women or women who are lactating. Patients who are not using contraception.~8. No known DPD-deficiency or known allergy to taxanes or platinum.~9. No signs of physical or mental illness that would prevent absorption of oral treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DOS2W Dose level 1A (Type: EXPERIMENTAL): Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
- DOS2W Dose level 2A (Type: EXPERIMENTAL): Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
- DOS2W Dose level 3A (Type: EXPERIMENTAL): Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
- DOS2W Dose level 4A (Type: EXPERIMENTAL): Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
- DOS3W Dose level 1B (Type: EXPERIMENTAL): Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.
- DOS3W Dose level 2B (Type: EXPERIMENTAL): Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.
- DOS3W Dose level 3B (Type: EXPERIMENTAL): Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject age 18 years or older, who requires Humira 40 mg SC every other week (eow) or every week (ew) for the treatment of rheumatoid arthritis, in accordance with the local Humira label.~* Subject must be a current, on-label user of Humira who rates his/her average Humira injection site related pain as at least 3 cm on a pain Visual Analogue Scale and has had at least 6 consecutive doses of Humira prior to Screening, or a biologic naïve subject who requires initiation of on-label treatment with Humira.~* Subject has diagnosis of rheumatoid arthritis (RA) as defined by the 1987 revised ACR classification criteria or the ACR/EULAR 2010 criteria,~* Female subjects are either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy and/or hysterectomy), or are practicing at least one method of birth control throughout the study and for at least 70 days after the last dose of study drug.~* All female subjects of childbearing potential must have a negative test for pregnancy on a serum sample at Screening and prior to study drug dosing on a urine sample obtained at Visit 1.~Exclusion Criteria:~* Subject has been treated with any investigational drug of a chemical or biologic nature within a minimum of 30 days or 5 half-lives (whichever is longer) of the drug prior to Visit 1.~* Any infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to Visit 1 or oral anti-infectives within 14 days prior to Visit 1.~* Prior exposure to natalizumab (Tysabri®) or efalizumab (Raptiva®).~* Known hypersensitivity to adalimumab or its excipients.~* History of demyelinating disease (including myelitis) or neurologic symptoms suggestive of demyelinating disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Current formulation adalimumab (Type: ACTIVE_COMPARATOR): One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe
- New formulation of adalimumab (Type: EXPERIMENTAL): One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven locally recurrent primary squamous cell cancer (SCC) of the head and neck or second primary SCC of the head and neck~  * More than 1 prior recurrence allowed if the first recurrence occurred at least 6 months after completion of prior radiotherapy~* Disease must be confined to the head and neck (above the clavicles)~* No primary SCC of the nasopharynx or salivary gland~* Prior irradiation of 45-75 Gy to the majority (75% or greater) of tumor volume~* Entire tumor volume must be included in a treatment field that limits the total spinal cord dose (prior and anticipated) to 50 Gy~  * Prior radiotherapy records, including simulation and portal films, available in order to assure that cord tolerance is not exceeded~* Measurable disease~* Ineligible for complete surgical resection~* No distant metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Zubrod 0 or 1~Life expectancy:~* No other concurrent illness that would limit survival~Hematopoietic:~* Granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 1.5 mg/dL~* Serum glutamate oxaloacetate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) no greater than 2 times normal\*~* Alkaline phosphatase no greater than 2 times normal\*~* \* Greater than 2 times normal allowed if no metastases by liver ultrasound or CT scan~Renal:~* Creatinine no greater than 1.5 mg/dL~Other:~* No other invasive malignancy within the past 2 years except in situ malignancies (e.g., carcinoma in situ of the cervix, carcinoma in situ of the breast, or nonmelanoma skin cancer)~* No other concurrent illness that would impair tolerance to therapy~* No grade 2 or worse pre-existing peripheral sensory neuropathy~* No hypersensitivity to E. coli derived products~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Prior chemotherapy allowed as a component of the primary treatment~* No prior chemotherapy for recurrent disease~* At least 6 months since prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* See Disease Characteristics~* At least 6 months since prior radiotherapy~Surgery:~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiation (BID) and chemotherapy (Type: EXPERIMENTAL): Radiation (BID), cisplatin and paclitaxel given on days 1-5 (Monday-Friday) in weeks 1, 3, 5 and 7. G-CSF given on days 6-13.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ciclosporin in HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Early (less than 2 years) HAM~* Progressing (within past 3 months) HAM~* Important to study the effect of therapy on disease that is most active as most likely to detect and measure improvement~Exclusion Criteria:~* HIV infection~* Tuberculosis, strongyloidiasis or other infection related to immune compromise~* Hepatitis B \& C viral infections~* Malignancy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ciclosporin (Type: EXPERIMENTAL): 48 weeks treatment with ciclosporin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Oral Antibiotic Treatment on C. Difficile

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients with microbiology-proven CDAD~* provides informed consent~* eligible to receive oral antibiotic therapy~Exclusion Criteria:~* prisoners~* pregnant women~* children \<18 years~* patients who have contra-indications for perianal swabs, those who has medical conditions that would invalidate the results of the swabs~* patients requiring intravenous therapy for treatment of CDAD~* patients who do not consent and those who withdraw consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fidaxomicin (Type: ACTIVE_COMPARATOR): 200 mg. 2 times a day for 10 days
- Metronidazole (Type: ACTIVE_COMPARATOR): 500 mg.orally 3 times daily for 10 days
- Vancomycin (Type: ACTIVE_COMPARATOR): 125 mg. orally 4 times a day for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Premixed Nitrous Oxide and Oxygen in Patient With Out-of-hospital Moderate Acute Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 years old~* Patients with a moderate acute pain (NRS score between 3 and 6)~Exclusion Criteria:~* Contraindication of premixed 50% nitrous oxide and oxygen~* Recent treatment of analgesic (less than 6 hours)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- premixed 50% nitrous oxide and oxygen (Type: EXPERIMENTAL): None
- medical air (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete